Celgene Provides Regulatory Update; Application for New Indication for REVLIMID in Newly-Diagnosed and Maintenance Multiple Myeloma Has Been Withdrawn from CHMP

Celgene International Sàrl, a subsidiary of Celgene Corporation

, is providing a regulatory update for REVLIMID (lenalidomide) and pomalidomide as treatments for multiple myeloma. We have decided to withdraw the new indication submission to the Committee for Medicinal Products for Human Use (CHMP) for REVLIMID (lenalidomide), which was intended for the maintenance treatment of newly diagnosed multiple myeloma patients who have not progressed following initial treatment with melphalan, prednisone and REVLIMID (lenalidomide), or maintenance therapy following autologous stem cell transplantation.